Amyris (NASDAQ: AMRS) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Monday. They currently have a $3.50 price target on the stock.
Several other analysts have also recently commented on the stock. Analysts at Raymond James upgraded shares of Amyris from an “underperform” rating to a “market perform” rating in a research note to investors on Thursday, February 21st.
Shares of Amyris traded up 6.64% during mid-day trading on Monday, hitting $3.05. Amyris has a one year low of $1.57 and a one year high of $6.00. The stock’s 50-day moving average is currently $3.28. The company’s market cap is $183.6 million.
Amyris last posted its quarterly earnings results on Tuesday, February 19th. The company reported ($0.49) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.51) by $0.02. The company had revenue of $5.90 million for the quarter, compared to the consensus estimate of $10.68 million. During the same quarter in the prior year, the company posted ($1.30) earnings per share. The company’s quarterly revenue was down 85.9% on a year-over-year basis. On average, analysts predict that Amyris will post $-1.22 earnings per share for the current fiscal year.
Amyris, Inc., formerly Amyris Biotechnologies, Inc. develops and provides renewable compounds for a variety of markets.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
